Merck KGaA (MKGAF)


Other OTC - Other OTC Delayed Price. Currency in USD
107.04-1.45 (-1.34%)
At close: 10:54 AM EDT
People also watch:
MKGAYESALYALIOFRHHBYBAYRY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open107.04
Prev Close108.49
Bid0.00 x
Ask0.00 x
Day's Range107.04 - 107.04
52wk Range94.87 - 111.02
1y Target EstN/A
Market Cap46.54B
P/E Ratio (ttm)29.52
Beta0.82
Volume13
Avg Vol (3m)2,145
Dividend & Yield1.20 (1.10%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • 24/7 Wall St.7 days ago

    How Much Medivation Can Really Fetch in a Buyout

    Medivation has been among the top future biotech mergers for quite some time. The problem is that we still have no idea which company will buy Medivation, nor do we know what price.

  • 2 Cancer Therapy Stocks That Are Ridiculously Cheap Right Now
    Motley Fool7 days ago

    2 Cancer Therapy Stocks That Are Ridiculously Cheap Right Now

    Agenus and Bellicum Pharmaceuticals are two hidden gems in the high-growth cancer drug space.

  • Barrons.com8 days ago

    Gilead Sciences: Still Dominating Hepatitis C But…

    After surveying doctors on the preferred hepatitis-C treatments, Baird's Brian Skorney and Neena Bitritto-Garg contend that Gilead Sciences (GILD) is likely to maintain its dominance over AbbVie (ABBV), Merck (MRK) and Johnson & Johnson (JNJ) but in what appears to be a shrinking market. In conjunction with script trends, physicians indicate that the market for treatment-eligible, easily accessible Hep C patients is shrinking, but that Gilead's share of the shrinking pie is continuing to grow.